COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #214 of 237
12/16 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Gönenli et al., Research Square, doi:0.21203/ (Preprint)
Prophylactic use of Hydroxychloroquine among Physicians working in Pandemic Hospitals
Source   PDF   Share   Tweet
Small prophylaxis survey showing lower, but not statistically significant, progression to pneumonia (3 of 148 HCQ, 12 of 416 control), RR 0.70, p = 0.77. There was a higher incidence of cases with HCQ, OR 1.19, p = 0.58, which may be due to survey bias, treatment self-selection, and inconsistent regimens. Improvement on severity may be related to the much higher HCQ concentration in lung tissue, and also reflect that binary PCR does not distinguish replication-competence. Details of the pneumonia numbers for treatment/control are from the author.

Gönenli et al., 12/16/2020, retrospective, Turkey, Middle East, preprint, survey, 4 authors.
risk of pneumonia, 29.7% lower, RR 0.70, p = 0.77, treatment 3 of 148 (2.0%), control 12 of 416 (2.9%).
risk of COVID-19 case, 18.9% higher, RR 1.19, p = 0.58, treatment 8 of 148 (5.4%), control 20 of 416 (4.8%), odds ratio converted to relative risk.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.